Metabolic syndrome and its pharmacologic treatment are associated with the time to castration-resistant prostate cancer.
Jiun-Hung GengAnna PlymKathryn L PenneyMark PomerantzLorelei A MucciAdam S KibelPublished in: Prostate cancer and prostatic diseases (2022)
Our study suggests that metabolic syndrome is a risk factor for earlier progression from castration-sensitive to castration-resistant prostate cancer and raises the possibility that treatment, such as statin use, may slow the time to progression.